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Current strategies for optimizing deep brain stimulation (DBS) therapy involve multiple
postoperative visits. During each visit, stimulation parameters are adjusted until desired
therapeutic effects are achieved and adverse effects are minimized. However, the efficacy
of these therapeutic parameters may decline with time due at least in part to disease
progression, interactions between the host environment and the electrode, and lead
migration. As such, development of closed-loop control systems that can respond to
changing neurochemical environments, tailoring DBS therapy to individual patients, is
paramount for improving the therapeutic efficacy of DBS. Evidence obtained using
electrophysiology and imaging techniques in both animals and humans suggests that
DBS works by modulating neural network activity. Recently, animal studies have shown
that stimulation-evoked changes in neurotransmitter release that mirror normal physiology
are associated with the therapeutic benefits of DBS. Therefore, to fully understand the
neurophysiology of DBS and optimize its efficacy, it may be necessary to look beyond
conventional electrophysiological analyses and characterize the neurochemical effects of
therapeutic and non-therapeutic stimulation. By combining electrochemical monitoring
and mathematical modeling techniques, we can potentially replace the trial-and-error
process used in clinical programming with deterministic approaches that help attain
optimal and stable neurochemical profiles. In this manuscript, we summarize the current
understanding of electrophysiological and electrochemical processing for control of
neuromodulation therapies. Additionally, we describe a proof-of-principle closed-loop
controller that characterizes DBS-evoked dopamine changes to adjust stimulation
parameters in a rodent model of DBS. The work described herein represents the initial
steps toward achieving a “smart” neuroprosthetic system for treatment of neurologic and
psychiatric disorders.
Keywords: deep brain stimulation (DBS), feedback control systems, local field potentials (LFP), fast scan cyclic
voltammetry (FSCV), machine learning, individualized medicine
INTRODUCTION
Neurologic and psychiatric disorders can be characterized by
motor, behavioral, cognitive, affective, or perceptual traits that
affect how individuals move, feel, think, and behave (Benabid
et al., 2005; Nemeroff, 2007; Williams and Okun, 2013). These
disorders affect over 94 million people in the United States alone
with health-care related costs exceeding $648 billion (Logothetis,
2003b; Benabid et al., 2005; Speert et al., 2012; Williams and
Okun, 2013). Although most individuals suffering from neuro-
logic and psychiatric disorders are successfully treated with a
combination of medications and therapy, up to 30% of patients
are unable to respond to standard therapeutic interventions
(Olanow et al., 2000; Benabid et al., 2005; Hamani et al., 2006;
Nemeroff, 2007; Williams and Okun, 2013). For these treatment-
resistant patients, high-frequency electrical stimulation of sub-
cortical brain structures, known as deep brain stimulation (DBS),
presents a highly successful therapeutic alternative (Benabid et al.,
2005; Williams and Okun, 2013). DBS is FDA-approved for the
treatment of Parkinson’s disease (PD) and essential tremor (ET)
(Benabid et al., 1987, 1991; Burchiel et al., 1999; Koller et al., 2001;
Obeso and Guridi, 2001; Simuni et al., 2002; Rehncrona et al.,
2003; Germano et al., 2004; Rodriguez-Oroz, 2004; Blomstedt and
Hariz, 2010; Moro et al., 2010; Weiss et al., 2013). Additionally,
DBS has received humanitarian device exemptions for dystonia
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and obsessive-compulsive disorder, and there are multiple studies
underway for the treatment of other neurologic and psychiatric
disorders (Benabid et al., 1987, 1991; Burchiel et al., 1999; Obeso
and Guridi, 2001; Simuni et al., 2002; Velasco et al., 2005; Lim
et al., 2007;Mueller et al., 2008; Blomstedt andHariz, 2010; Denys
et al., 2010; Fisher et al., 2010; Ramasubbu et al., 2013).
Brain stimulation has been an important tool in the field of
neurosurgery pioneered by Spiegel and Wycis (Blomstedt and
Hariz, 2010). Intra-operative electrical stimulation of neural tis-
sue has been used since the early days of human stereotaxis to
identify surgical targets (Gildenberg, 2003, 2005). Application of
brain stimulation in modern-day neurosurgery was revolution-
ized by Benabid and colleagues, who used high frequency stimu-
lation (typically 100–130Hz) delivered directly into specific brain
regions to mimic the effects of surgical lesions without perform-
ing any tissue resection (Benabid et al., 1987, 1991; Blomstedt
and Hariz, 2010). DBS achieves therapeutic benefits by deliver-
ing electrical currents to specific anatomical targets within the
brain via multi-contact electrodes connected to implanted pulse
generators. In DBS therapy, a balance between maximal clini-
cal improvement and minimal stimulation-induced side effects is
typically achieved by adjusting active electrode contacts, stimulus
frequency, amplitude, and pulse duration.
Clinical DBS programming is an iterative process in which
stimulation parameters are adjusted in order to maximize ther-
apeutic benefits while minimizing side effects (Morishita et al.,
2013) Although many DBS patients require minimal stimula-
tion adjustment following surgery, many more require several
months of regular parameter adjustments before optimal ther-
apeutic results can be achieved (Okun et al., 2005; Bronstein
et al., 2011; Kluger et al., 2011). However, sustaining these ther-
apeutic benefits requires subsequent adjustment of stimulation
parameters every fewmonths (Mayberg et al., 2000, 2005; Deuschl
et al., 2006; Moro et al., 2006; Frankemolle et al., 2010; Mure
et al., 2011). Therefore, existing clinical programming and stim-
ulation paradigms are poorly suited to cope with the dynamic
and comorbid nature of most neurologic disorders. This, in turn,
highlights the need for dynamic feedback systems that can contin-
ually and automatically adjust stimulation parameters in response
to changes within the environment of the brain.
THERAPEUTIC STIMULATION PARADIGMS
The therapeutic success of DBS depends not only on accurate
surgical targeting and electrode implantation, but also on the
ability to optimize stimulation parameters to maximize therapeu-
tic benefits while minimizing side effects. Clinical strategies for
therapeutic DBS programming require multiple post-operative
visits during which experienced clinicians perform clinical eval-
uations and corresponding device programming. In each visit, a
series of inputs (active contacts, stimulus amplitude, pulse width,
and frequency) are adjusted in an attempt to minimize adverse
effects while maximizing clinical benefits. Although this strat-
egy has provided significant patient benefit, the results are far
from optimal. First, this open loop strategy relies on the sub-
jective experiences of both the patient and clinician, without
providing objective feedback to support parameter optimization.
Second, the therapeutic response observed in this acute setting
does not guarantee sustained therapeutic effects. Disease progres-
sion, environmental factors, and behaviorally induced changes in
network activity can all render therapeutic stimulation ineffective,
requiring additional programming sessions (Obeso and Guridi,
2001; Hunka et al., 2005; Kupsch et al., 2011). Third, the pro-
cedure is costly and time consuming. As such, only a fraction
of the stimulation parameter space can be practically explored
during each session. Fourth, DBS device programming can dif-
fer according to the target chosen, the orientation of the electrode
relative to the target, the disorder being treated, and the symp-
toms being treated for a given disorder (Velasco et al., 2007; Ricchi
et al., 2012;Min et al., 2013;Miocinovic et al., 2013). Additionally,
the timing of programming as well as the waiting time between
adjustments can influence when different therapeutic responses
can be observed, and these responses also vary between disor-
ders (e.g., Tremor is nearly immediate, whereas depression could
take several weeks to observe the effect of a disorder) (Velasco
et al., 2007; Ricchi et al., 2012; Min et al., 2013; Miocinovic
et al., 2013). Therefore, it is necessary to implement DBS con-
trol strategies that can adjust stimulation parameters in real-time
according to quantifiable and objective neurochemical, physio-
logical, and behavioral changes while reducing the frequency of
clinical interventions. However, before such control strategies can
be implemented, it is necessary to improve the understanding of
the cellular mechanisms responsible for the network effects of
DBS.
The cellular response of single neurons to extracellular electri-
cal fields has been well characterized over short time scales (Smith
and Grace, 1992; Benazzouz et al., 2000; Hashimoto et al., 2003;
Maurice et al., 2003; Kita et al., 2005; Miocinovic et al., 2006).
It is known that excitation of efferent axons or fibers of passage
near the site of stimulation results in network changes in neuro-
transmission and electrical activity (Grill et al., 2004; McIntyre
et al., 2004a,b; Johnson et al., 2008; McIntyre and Hahn, 2010;
Shah et al., 2010). Furthermore, functional and metabolic imag-
ing studies have shown that successful treatment of neurologic
and psychiatric disorders is associated with metabolic normal-
ization in proximal and distal regions of the brain (Mayberg
et al., 2000, 2005; Mure et al., 2011). The precise relationships
between therapeutic improvement and changes in metabolic pat-
terns remain unknown. As such, current research efforts focus on
the use electrophysiology and electrochemistry to elucidate the
network effects of DBS (Bledsoe et al., 2009; Lee et al., 2011; Vitek
et al., 2012).
REAL-TIME MONITORING OF NEURAL ACTIVITY
Signaling within the brain occurs both electrically and chemi-
cally. Technological advances in neural activity monitoring have
enabled real-time investigation of cellular and molecular dynam-
ics using electrophysiological and neurochemical probes. While
the most used technique involves electrophysiological monitor-
ing of extra-cellular neuronal activity (Smith and Grace, 1992;
Benazzouz et al., 2000; Hashimoto et al., 2003; Maurice et al.,
2003; Johnson et al., 2005; Kita et al., 2005; Miocinovic et al.,
2006) recent advances in electrode technology allow in vivomon-
itoring of synaptic neurotransmitter activity (Roham et al., 2007;
van Gompel et al., 2010).
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Electrophysiological analysis has been widely used to study
stimulation-evoked changes in brain activity, such as increased
pallidal (Hashimoto et al., 2003; Kita et al., 2005; Miocinovic
et al., 2006) and nigral activity (Smith and Grace, 1992;
Benazzouz et al., 2000; Maurice et al., 2003) during subthalamic
nucleus (STN) DBS. This has been accomplished by record-
ing single neuron activity (single unit recordings), activity from
local groups of neurons (multi unit activity, local field poten-
tials), and distributed signals representing global brain activity
[electrocorticograms (ECoGs), electroencephalograms (EEGs)].
Alternatively, neurochemical analysis techniques such as micro-
dialysis, amperometry, and voltammetry, can detect local changes
in neurotransmitter concentration evoked by internal and exter-
nal mechanical, electrical, and chemical stimuli (Dale et al., 2005;
Wightman, 2006). Neurochemical recordings have been used to
monitor in vivo release of analytes such as oxygen, dopamine,
adenosine, serotonin, and glutamate in small and large animal
models of DBS (Agnesi et al., 2009; Bledsoe et al., 2009; Chang
et al., 2009; Kimble et al., 2009; Griessenauer et al., 2010; Shon
et al., 2010a,b).
SINGLE-UNIT RECORDINGS
Single unit recordings capture the activity of distinct neurons
in vivo by placing a high-impedance microelectrode within the
extracellular space surrounding the cell body. These electrodes,
having surface areas under 2× 10-5 cm2 (Loffler, 2012), record
extracellular potentials representative of intracellular action
potentials from neurons adjacent to the electrode tip. The high
spatial and temporal resolution provided by single unit record-
ings allows for precise measurements of neuronal spikes (Buzsáki
et al., 2012). However, activity from single units can be difficult
to isolate due to crosstalk from neighboring cells (Bai and Wise,
2001). Additionally, single unit recordings can be biased toward
activity from larger (e.g., pyramidal) cells (Buzsáki et al., 1983).
Furthermore, electrode migration, immune responses (e.g., glial
scarring), and disruption of surrounding neural tissue interfere
with signal quality and limit reliable single unit activity to acute
recording conditions (Carter and Houk, 1993; Polikov et al.,
2005).
MULTI-UNIT RECORDINGS
Multi unit recordings capture fast spiking activity from groups
of neurons using high-impedance microelectrode arrays. Similar
to single unit recordings, this technique provides good spatial
and temporal resolution reflecting synaptic events occurring at
high frequencies (>800Hz) (Logothetis, 2003a,b; Mattia et al.,
2010). Unfortunately, multi-unit recording arrays suffer from stiff
form factors that result in shear-induced inflammation of the sur-
rounding tissue (Cheung, 2007). Furthermore, recording can only
occur from the tips of the electrodes, limiting recording selectivity
(Maynard et al., 1997).
LOCAL FIELD POTENTIALS
Local field potential (LFP) analysis is an electrophysiological
technique for detecting changes in brain activity that offers
great potential for understanding the network effects of DBS
(Tsang et al., 2012; Priori et al., 2013). This technique is capa-
ble of recording chronic electrical activity directly from single
and multiple neural units using micro and macro electrodes
implanted within the nucleus of interest (Bronte-Stewart et al.,
2009; Giannicola et al., 2012). LFPs are typically used to record
low-frequency changes in activity across groups of neurons within
a volume of interest (Andersen et al., 2004; Buzsáki et al., 2012;
Rosa et al., 2012). These activity changes reflect a weighted aver-
age of integrative processes and associations between cells that
can be detected over longer distances through extracellular space
(Logothetis, 2003a,b; Bronte-Stewart et al., 2009). Unfortunately,
the longer recording range of LFP techniques is associated with
decreased spatial resolution. Despite this limitation, LFP record-
ings can be performed in real-time using the same DBS electrode,
which eliminates the need for additional electrode penetrations
(Rossi et al., 2007). Therefore, local field potentials present a good
starting point for establishing closed-loop neurostimulation con-
trol systems (Rosin et al., 2011; Santaniello et al., 2011; Berényi
et al., 2012; Little et al., 2013).
GLOBAL FIELD POTENTIALS
Analysis of global brain activity can be used to identify both
spontaneous and event-related responses from large groups of
neurons. Whole-brain electrophysiological brain activity (i.e.,
global field potentials) is typically measured using far-field sen-
sors located on the scalp (EEG) or directly on the brain surface
(ECoG). These global field potentials can be used to identify
information regarding high-level sensory processing, perception,
and locomotor activity (Issa and Wang, 2013). For example, EEG
signals with low spatial resolution can be recorded non-invasively
by non-surgically attaching recording electrodes to the scalp.
Alternatively, ECoG signals offer increased spatial resolution, but
recording electrodes must be surgically attached at the cortical
surface (Buzsáki et al., 2012). Despite the advantages of global
field potentials, these signals do not provide insight into activity
changes within specific subcortical structures. As such, a system
that combines activity analysis within cortical (e.g., EcOG) and
subcortical (e.g., LFP) networks should provide a better depiction
of network dynamics which, in turn, will be required to develop
optimal closed-loop stimulation paradigms (Rosa et al., 2012).
NEUROCHEMICAL RECORDINGS
Neurochemical sensing allows real-time characterization of neu-
ral activity with high spatial resolution and signal specificity
(Lee et al., 2004). Microdialysis, amperometry, and voltammetry
are three widely used techniques for neurochemical monitoring
(Blaha and Phillips, 1996).
Microdialysis is a technique for sampling different analytes
and determining their concentration in extracellular fluid (Chefer
et al., 2009). This technique offers excellent specificity, selectiv-
ity, and sensitivity for quantifying neurotransmitter release in
a laboratory setting (Watson et al., 2006). However, it suffers
from limited temporal resolution (Smolders et al., 1997; Khan
et al., 1999). Therefore, microdialysis is not suitable for real-time
clinical application in closed-loop systems.
Amperometry is an alternative technique for measuring ana-
lytes in the extracellular space. Amperometric recordings involve
the application of a fixed electric potential through a carbon fiber
microelectrode (CFM) placed in close proximity to the target
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FIGURE 1 | Stimulation-evoked dopamine responses. (A) Dopamine redox
reactions at the tip of a carbon fiber microelectrode during fast scan cyclic
voltammetry. As the potential applied to the electrode increases from −0.4 to
0.0 V, extracellular dopamine is reduced (reduction peak at −3.5 nA). As the
applied potential is further increased from 0.0 to 1.0 V, dopamine is oxidized
(oxidation peak at 3.5 nA). Measured current background is shown in red. (B)
Pseudo-color representation of dopamine oxidation current at +0.6 V at DBS
onset (100Hz, 2ms, 300µA).
cells (Gale et al., 2013; Tye et al., 2013). These CFM are coated
with specific enzymes known to react with non-electrolytic ana-
lytes of interest, resulting in electroactive products that can be
electrically measured (Oldenziel et al., 2004). This allows con-
tinuous monitoring of changes in electrical currents within the
surrounding extracellular fluid. The detected changes in current
are caused by oxidative reactions between the applied potential
and analyte molecules within the extracellular space (van Gompel
et al., 2010). The downfall of this technique is the high complex-
ity associated with chronic in vivo measurements, which require
continuous enzyme delivery to detect the breakdown products of
the neurotransmitter of interest (Jacobs et al., 2010).
Analogous to amperometry, voltammetry provides real-time
high-resolution analyte measurements (Blaha et al., 1990).
Specifically, fast scan cyclic voltammetry (FSCV) is a voltamme-
try technique in which a linearly varying potential is applied to
a carbon fiber electrode, allowing for oxidation and reduction
of surrounding electroactive molecules to take place (Robinson
et al., 2003; Lee et al., 2007). The magnitudes of the analyte oxi-
dation and reduction current peaks are directly proportional to
the concentration of analyte oxidized and reduced at the electrode
surface (Atcherley et al., 2013). Furthermore, the resulting electri-
cal current vs. applied potential relationships (Figure 1) provide
a chemical signature (i.e., voltammogram) that allows identifica-
tion of specific neurotransmitters or other electroactive analytes
(Robinson et al., 2003). FSCV detection of analytes is limited to
electroactive molecules such as dopamine, adenosine, and oxy-
gen (van Gompel et al., 2010). Furthermore, the lifetime of CFM
is limited to a few months (Kim et al., under review), restricting
clinical application of FSCV detection methods to intraoperative
approaches.
SMART DBS CONTROL
Clinical DBS systems follow an open-loop paradigm. That is,
stimulation parameters are pre-programmed into the DBS device
and held constant until the next programming session, regardless
of the internal state of the system or environmental factors
(Foltynie and Hariz, 2010). In contrast, closed-loop DBS systems
rely on sensor feedback to monitor the environment and inter-
nal state of the system in order to adjust stimulation parameters
accordingly (Abbott, 2006; Fagg et al., 2007). That is, stimula-
tion parameters (e.g., stimulation frequency, stimulus amplitude,
etc.) are automatically adjusted to maintain specific therapeu-
tic outputs such as tremor suppression in the presence of dis-
turbances, environmental perturbations, and internal network
changes (Figure 2). To date, development of closed-loop neuro-
prosthetic devices has largely focused on using electrophysiolog-
ical activity as feedback signals (Avestruz et al., 2008; Skarpaas
and Morrell, 2009; Rosin et al., 2011; Basu et al., 2013; Grant and
Lowery, 2013). Neurochemical-based feedback, however, offers
the prospect of finer control of stimulation-induced effects, as
it allows activity monitoring from individual types of neurons
by virtue of their neurotransmitters. The ability to use neuro-
chemical feedback to control DBS has been demonstrated by
characterizing glutamate release using mathematical models link-
ing electrical stimulation to glutamate release in a rat model of
DBS (Behrend et al., 2009). Thus, chemical sensing presents a
unique opportunity for developing closed-loop smart neurocon-
trol systems that are optimized for specific disorders and targets,
and which can account for intra- and inter-patient variability.
NEUROCHEMISTRY OF DBS
Studies using small and large animal models suggest that ther-
apeutic DBS coincides with changes in neurotransmitter release
(Lee et al., 2004; Shon et al., 2010a,b). It has been established
that dopaminergic cell loss in the substantia nigra leads to stri-
atal dopamine deficiency and movement abnormalities in PD
patients (MacDonald et al., 2013). It has also been shown that
therapeutic STN DBS for treatment of PD decreases the need
for exogenous levodopa (Moro et al., 1999; Molinuevo et al.,
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FIGURE 2 | Real-time closed-loop deep brain stimulation system.
Clockwise from bottom left: (1) Schematic of the human brain with two
electrodes (inset) for simultaneous stimulation (gray contacts) and recording
of neural activity (blue contacts). (2) Example voltammogram, local field
potentials, and single unit activity signals representing recorded
neurochemical and electrophysiological neural activity. (3) Computational
model of neurochemical and electrophysiological dynamics allows generation
and optimization of data beyond the time constraints imposed by
experimental conditions. (4) Smart controller uses existing neural activity to
predict stimulation parameters required to achieve therapeutic
neuromodulation. (5) Predicted stimulation parameters are applied to the
brain using an implanted neurostimulation system.
2000) and has been hypothesized to increase striatal dopamine
release (Lee et al., 2009). Complementing findings in electro-
physiological and neurochemical sensing studies have shown that
STN DBS evokes dopamine release in the striatum of parkinso-
nian rats (Blaha and Phillips, 1996; Lee et al., 2006). Similarly,
stimulation-evoked adenosine release has been recorded intra-
operatively in the ventral intermediate nucleus of the thalamus
in human patients undergoing DBS for treatment of ET (Chang
et al., 2012). However, the specific relationship between DBS and
neurochemical activity changes remains unknown. Therefore,
understanding the relationships between stimulation parame-
ters and neurotransmitter concentration levels is paramount for
developing closed-loop DBS control strategies.
In the following paragraphs, we describe a proof-of-principle
approach to closed-loop DBS that automatically adjusts stimula-
tion parameters in order to sustain stable dopamine levels in a
rodent model of DBS. The paradigm proposed herein uses FSCV
to quantify striatal dopamine release evoked by medial forebrain
bundle (MFB) DBS. Additionally, this paradigm relies on non-
linear regression, computational modeling, and constrained
optimization techniques to parameterize stimulation-evoked
dopamine responses. The inverse dynamics of stimulation-evoked
dopaminergic responses are modeled using artificial neural
networks (ANN), which also predict stimulation parameters
required for sustaining target dopaminergic concentration levels.
The performance of this closed-loop paradigm was evaluated by
comparing target dopaminergic responses to in vivo dopaminer-
gic responses achieved using ANN-predicted stimulation parame-
ters (Figure 4). While focused on DBS of ascending dopaminergic
fibers in theMFB for evoking dopamine release in the rat striatum
(Agnesi et al., 2009), this closed-loop paradigm is applicable to a
variety of analytes, targets, and neurologic disorders.
EXPERIMENTAL PARADIGM
To quantify the dynamics of stimulation-evoked dopamine
release, recording FSCV CFM and bipolar DBS macroelectrodes
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were implanted into the striatum and MFB, respectively, in four
anesthetized rats. All animal procedures were performed accord-
ing to the guidelines of the Mayo Clinic Institutional Animal
Care and Use Committee (IACUC). Animals were kept on a
standard 12 h light-dark cycle with access to food and water
ad libitum in conventional housing in accordance with National
Institutes of Health (NIH) and US Department of Agriculture
guidelines.
Animals were anesthetized and the head was fixed in a
Kopf stereotactic frame (David Kopf Instruments, California)
for electrode targeting. Following brain exposure, one bipolar
stimulating electrode, one FSCV recording electrode, and one
silver-chloride reference electrode was inserted into the left MFB,
striatum, and contralateral cortex, respectively. Recording elec-
trodes were allowed to stabilize within the tissue environment
for 20min. Finally, the electrodes were connected to a wireless
stimulator and neurotransmitter sensor for real-time detection of
stimulation-evoked dopamine release (Kimble et al., 2009; Chang
et al., 2013).
Following electrode implantation, a comprehensive range of
stimulation parameters (Table 1) was used to determine the mag-
nitudes and temporal patterns of stimulation-evoked dopamine
release. Stimulation was divided into 65 20-s bins. Each bin corre-
sponded to one combination of stimulation parameters delivered
through the active electrode contact. Each stimulation bin was
followed by a stabilization and washout period of 180 s.
STIMULATION-EVOKED NEUROCHEMICAL MONITORING
Stimulation-evoked dopamine measurements were obtained
by changing the CFM potential from a resting potential of
−0.4–1.3 V and back, at a rate of 400V/s. This triangular wave-
form was repeated at a frequency of 10Hz (Chang et al., 2012).
The CFM was held at the resting potential between scans. We
converted the measured oxidation and reduction current peaks
to dopamine concentration using post-operative in vitro flow
injection analysis calibration of each CFM (Griessenauer et al.,
2010). Our preliminary results showed that as MFB DBS ampli-
tude increases, extracellular dopamine levels within the striatum
also increase (Figure 3A). A similar response is also observed
as pulse duration is increased from 0.1 to 2.0ms (Figure 3B).
Changes in frequency, however, give rise to a different dopamin-
ergic response. Maximum response was observed at 100Hz, fol-
lowed by a decrease in dopamine oxidation currents at higher
frequencies (Figure 3C).
Table 1 | Stimulation parameters.
Frequency (Hz) Amplitude (µA) Pulse width (ms) Duration (s)
60 100–450 2.0 2
100 100–450 2.0 2
20–200 250 2.0 2
20–200 350 2.0 2
60 300 2.0 2
100 300 0.1–2.0 2
60 300 2.0 0.5–8
NEUROCHEMICAL RESPONSE MODELING
Implementation of neurochemically-driven closed-loop DBS
control strategies requires characterization of the relationship
between electrical stimulation and neurochemical responses.
To characterize this relationship, stimulation-evoked FSCV
dopamine signals were low pass filtered (5th-order Butterworth
filter, 100Hz cutoff frequency) to remove signal noise.
Additionally, the responses to individual stimuli were char-
acterized using a combination of 7th-degree polynomial and
2nd-order exponential mathematical models. The mathematical
model parameters (eight for the polynomial fit and four for the
exponential fit) and corresponding stimuli were presented to a
double-layer feedforward ANNwith sigmoidal and linear transfer
functions (Lujan and Crago, 2009). The hidden layer contained
150-hidden neurons. The inputs to the ANN consisted on the
stimulation frequency, pulsewidth, and stimulus amplitude,
while system outputs corresponded to the 12 model parameters.
Initial weights and biases were selected at random for 10 different
initial conditions. Ten corresponding ANNs were trained on 80%
of the data (selected at random) using the Levenberg-Marquardt
algorithm. The trained ANN with the lowest generalization error,
calculated using the remaining 20% of data, was selected as a
system model. The resulting system model, when combined
with constrained optimization for minimization of stimulation
energy, can identify and eliminate mathematical redundancies
for the optimal design of the closed-loop controller (Lujan and
Crago, 2009).
STIMULATION PREDICTION
In order to provide optimal stimulation, a predictive model
that characterizes the inverse relationship between stimulation
parameters and dopamine levels was created. Similarly to the
system model, the predictive model was created using a double-
layer ANN with 600 hidden neurons, as well as sigmoidal and
linear transfer functions (Lujan and Crago, 2009). The inputs
to the predictive model corresponded to the sets of 12 model
parameters, while the outputs corresponded to the three stimu-
lation parameters. This inverse model was then used to predict
the stimulation parameters required to sustain specific extra-
cellular dopamine levels within the striatum, thus allowing for
feedback control. This was followed by stimulation of the MFB
using the predicted parameters, and simultaneous recording
of extracellular dopamine levels. Root mean squared (RMS)
errors between experimentallymeasured and desired stimulation-
evoked dopamine responses were used to determine controller
efficacy. Least-squares regression analysis of the dependencies of
actual dopamine levels on target levels was used in an effort to
identify systematic (e.g., slope, offset) sources of error (Lujan and
Crago, 2009).
CLOSED-LOOP CONTROL
Our preliminary results in four anesthetized rats suggest that
mathematical models can be used to describe the relationships
between stimulation-evoked extracellular dopamine responses
and DBS parameters (R2 = 0.8). Furthermore, these results
show that adjusting stimulation parameter intensity can mod-
ulate dopamine concentration, and that we can use ANN to
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FIGURE 3 | Stimulation-evoked dopamine release characterization in
four anesthetized rats. A carbon-fiber recording electrode was implanted
into the left striatum and a bipolar stimulating electrode was placed within
the ipsilateral medial forebrain bundle. A reference silver-chloride electrode
was implanted into the contralateral cortex. Current amplitude (A), pulse
duration (B), and frequency (C) were individually varied while the remaining
stimulation parameters were held constant. Stimulus duration was set at 2 s
for all experiments described above.
dynamically predict stimulation parameters required to adjust
stimulation-evoked dopamine levels (Figure 4). However, to fur-
ther understand the network effects of DBS and optimize the
therapeutic efficacy of stimulation, it may be necessary to com-
bine electrophysiological (e.g., LFP, ECoG) and neurochemical
feedback signals.
DISCUSSION
Frequent adjustment of stimulation settings has been shown to
improve the efficacy of DBS therapy (Rosin et al., 2011), which
highlights the nature of the changing brain environment. Thus,
a smart, automated system capable of dynamically adjusting
stimulation parameters in response to a changing environment
becomes critical for improving the therapeutic efficacy of DBS
therapy. The proof-of-principle closed-loop DBS system pro-
posed above offers the potential for maintaining therapeutic
responses during disease progression. By taking advantage of
mathematical models, the paradigm presented here can poten-
tially replace the trial-and-error process currently used in clinical
programming with deterministic approaches, thereby achieving
optimal therapeutic outcomes while minimizing the number of
clinical interventions. In turn, this will ultimately reduce required
hospital visits and associated healthcare costs (Fraix et al., 2006).
Before automated adjustment of stimulation parameters can
be clinically implemented, however, several key clinical questions
need to be investigated. Specifically, the relationship between neu-
rotransmitter levels and symptoms of neurologic disease needs
further elucidation. For example, there is indirect evidence to sug-
gest that dopamine depletion plays a role in the symptoms of PD
and that dopaminergic medications have a therapeutic response.
However, precise concentration changes that occur with symp-
tom exacerbation and amelioration are unknown. Additionally,
multiple neurotransmitters may play a critical role in the disease
(Fitzgerald, 2014). Thus, optimal neurotransmitters and opti-
mal recording locations should be identified for each disorder.
Future work should be directed toward validating closed-loop
algorithms, correlating neurotransmitter release to clinical benefit
in a large animal disease model of Parkinsonism or ET.
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FIGURE 4 | Controller performance. (A) Comparison of target (dotted
lines) and actual (solid lines) dopaminergic responses evoked by
stimulation parameters predicted by the artificial neural network
controller. Two typical responses are shown. (B) Target and actual
responses were compared using linear regression and Pearson’s
correlation (R2 = 0.8538).
Similarly, an important technical barrier that needs to be
addressed is that chronic recordings are not possible using cur-
rent electrode technology. CFMs are subject to electrode fouling
due to the charge imbalance of the waveforms required for FSCV.
Efforts are underway to develop electrochemical-sensing tech-
niques capable of extending electrode longevity by renewing the
electrochemically active surface following adsorption of chem-
ical species (Takmakov et al., 2010). Additionally, it has been
reported that diamond coating may potentially prolong the life
of recording electrodes (Roham et al., 2007). Once these tech-
nologies have been developed, they will need to undergo extensive
safety and efficacy testing and validation in pathological animal
models before advancing to clinical trials.
CONCLUSIONS
Conventional neuromodulation systems have been successful at
achieving therapeutic outcomes in patients with neurologic and
psychiatric disorders. However, limitations in existing technol-
ogy make ensuring optimal benefits a difficult and expensive
endeavor. Correlation of multi-modal electrophysiological and
neurochemical recordings may provide new insight into the cellu-
lar and molecular mechanisms of therapeutic neuromodulation.
Therefore, development of smart DBS controllers that rely on
the relationships between neurochemical and electrophysiologi-
cal recordings with the clinical effects of DBS offers the potential
of replacing the trial-and-error process used in clinical program-
ming with a deterministic approach. Furthermore, the versatility
and adaptability of such controllers will allow expansion of the
clinical indications that can be treated with DBS while tailor-
ing its application to individual patients and symptoms. In turn,
these will likely improve clinical outcomes, reduce the time and
frequency of patient visits, and lower overall health care costs.
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